ArticleACS omega2025
Layered Double Hydroxide LDH-Loaded miR-141-3p Targets RAB10 Suppressing Cellular Autophagy to Reverse Paclitaxel Resistance in Breast Cancer.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Relationship Between Climate Change and Breast Cancer and Its Management and Preventative Implications in South Africa.International journal of environmental research and public health · 2025Pooled it
- Bioinformatics Analysis of microRNAs Associated with Metastatic Potential in Breast Cancer.Biology · 2026Article
- Role and underlying mechanisms of miR‑200 family in breast cancer (Review).International journal of oncology · 2026Review
- Targeting the redox-programmed cell death axis in breast cancer: from molecular mechanisms to therapeutic resistance.Cell death discovery · 2025Review
- Bioactive LDH nanoplatforms for cancer therapy: Advances in modulating programmed cell death.Materials today. Bio · 2025Review
- Integrative proteomics and metabolomics analyses reveals the regulation of autophagy and ferroptosis by RAB10 through Slc37a2/mTOR pathway in breast cancer.Cellular and molecular life sciences : CMLS · 2025Article
- Engineered exosomes: a promising design platform for overcoming cancer therapy resistance.Frontiers in cell and developmental biology · 2025Review
- eIF3b-driven autophagy and Wnt/β-catenin crosstalk: a novel regulatory axis in adriamycin resistance of breast cancer.Oncology reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autophagy is a cellular protective mechanism. As tumor cells are stimulated by drugs, autophagy is activated to increase their resistance to drugs. In gene regulation, microRNA (miRNA) plays a vital role. The diagnostic and prognostic potential of various miRNAs in cancer has been recognized, and for several years, miRNA-based therapeutic approaches have garnered significant interest in the oncology field. RAB10, a member of the RAB guanosine triphosphatase family, has been reported that it contributes to tumor resistance to chemotherapy. The bionanomaterial layered double hydroxide (LDH) is considered as an ideal gene delivery vehicle because of its nontoxicity, good biocompatibility, and slow drug release. According to our findings, we proved that miR-141-3p mediated breast cancer resistance to paclitaxel (PTX) by inhibiting autophagy through downregulation of RAB10, and LDH@miR-141-3p increased breast cancer cell sensitivity to PTX treatment, which provided a new idea for antitumor therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.